DOCSLIB.ORG

Day-2-Speaker-12-Wolfe-Scleroderma.Pdf

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Day-2-Speaker-12-Wolfe-Scleroderma.Pdf Scleroderma gives Connective Disease a bad name! 1. Scleroderma (limited and diffuse) always causes significant skin tightening. 2. ANA abs are always positive. 3. Symptoms can include lung, skin, GI, vascular, heart, and renal. 4. Raynauds is always bad in the scleroderma conditions. 5. Treatment of the various 0% 0% 0% 0% 0% symptoms is almost always easy. 1 2 3 4 10 5 Countdown • Major criterion or two minor criteria for diagnosis • Major criterion • Proximal Scleroderma • Minor criteria • Sclerodactyly, digital pitting or scars, or loss of substance from finger pad, bibasilar pulmonary fibrosis • Localized scleroderma • Systemic sclerosis Morphea Diffuse cutaneous Limited cutaneous Linear scleroderma CREST syndrome “En coup de sabre” Systemic sclerosis sine scleroderma • Overlap syndromes • Scleroderma-like syndromes • Toxin- or drug-induced scleroderma Vinyl chloride Organic solvents and epoxy resins Eosinophilic myalgia syndrome (L-tryptophan) Toxic oil syndrome Bleomycin • Vibration injury • Scleromyxedema • Scleredema • Eosinophilic fasciitis • Graft-versus-host disease • Antibody Prevalence Clinical Associations • Anti-Topoisomerase 20-40% Diffuse skin disease ILD, Increased Mortality, cardiac Disease • Anti-Centromere 20-40% CREST, Digital loss, Pulmon HTN, PBC • RNA Polymerase 4-20% Renal crisis, card- iac disease, diff- use skin disease • PM-SCL 1% Myositis • RNP 5% MCTD • U3RNP 8% African-american males, diffuse skin disease, pulmonary disease, • Episodic, reversible digital skin color change white to blue to red well-demarcated • Due to vasospasm • Usually cold-induced • Primary (Raynaud’s disease) and secondary forms • Connective tissue diseases Scleroderma, systemic lupus erythematosus, MCTD, undifferentiated CTD, Sjogren’s syndrome, dermatomyositis • Occlusive arterial disease Atherosclerosis, anti-phospholipid antibody syndrome, Buerger’s disease • Vascular injury Frostbite, vibratory trauma • Drugs and toxins Beta blockers, vinyl chloride, bleomycin, ergot, amphetamines, cocaine • Hyperviscosity/cold-reacting proteins Paraproteinemia, polycythemia, cryoglobulinemia, cryofibrinogenemia, cold agglutinins Feature Primary Raynauds Systemic Sclerosis • Sex F:M 4:1 F:M 3:1 • Age at Onset Puberty 25 yrs or older • Frequency Usually <5/day >5-10/day • Precipitants Cold, emotional stress Cold • Ischemic injury Absent Present • Other vasomotor Yes Yes • Phenomenon • ANAs Absent 90-95% • Anti-Centromere Absent 50-60% • Anti-SCL-70 ab Absent 20-30% • Abn capillaroscopy Absent >95% • The diagnosis of MCTD can be made if 3 (one of which must be myositis or synovitis) of 5 clinical criteria and anti-RNP are present • Serologic criteria • anti-RNP antibodies • Clinical criteria • swollen hands, synovitis, clinical or biopsy-proven myositis, Raynaud’s phenomenon, acrosclerosis with or without proximal systemic sclerosis • Major criterion or two minor criteria for diagnosis Episodic, reversible digital skin color change white to blue to red • Major criterion well-demarcated • ProximalDue scleroderma to vasospasm Usually cold-induced • Minor criteria Primary (Raynaud’s disease) and secondary • Sclerodactyly forms • Digital pitting or scars or loss of substance from finger pad • Bibasilar pulmonary fibrosis System 0 (normal) 1 (mild) 2 (moderate) 3 (severe) 4 (end-stage) General Normal Weight loss of 5.0- Weight loss of 10.0- Weight loss of 15.0- Weight loss of 20+kg 9.9kg or hematocrit 14.9kg or hematocrit 19.9kg or hematocrit or hematocrit <25.0 33.0-36.9 29.0-32.9 25.0-28.9 Raynaud’s Normal Vasodilator requiring Digital pitting scars Active digital pit Digital gangrene ulceration Skin score 0 1-14 15-29 30-39 40+ Finger to palm (cm) <1 1.0-1.9 2.0-3.9 4.0-4.9 5.0+ Proximal Weakness None Mild Moderate Severe Cannot walk GI Status Normal Requires antireflux High dose antireflux Malabsorption TPN required medication or medication or syndrome or episodes abnormal small bowel antibiotics for of pseudo-obstruction series bacterial overgrowth Lung Normal FVC or DLCO 70-80% FVC or DLCO 50-69% FVC or DLCO 50% Oxygen required predicted or rales or predicted or mild predicted or fibrosis on chest x-ray pulmonary moderate-severe hypertension pulmonary hypertension Heart Normal ECG conduction Arrhythmia or RVE + LVEF <40% Congestive heart defect of LVEF 45- LVE or LVEF 40-44% failure or arrhythmia 49% requiring medication Kidney Normal Creatinine 1.3-1.6 or Creatinine 1.7-2.9 or Creatinine 3.0+ Requires dialysis uprot 2+ uprot 3-4+ • This is the really difficult part of the disease process • There is no specific drug that is available that is known for sure to stop the fibrotic process. 1. Calcium Channel Blockers 2. ACE Inhibitors, ARBs 3. PDE4 Inhibitors? 4. Bosentan (Tracleer) 5. Surgery (Which can include debridement of necrotic tissue or abcess drainage but un- fortunately often is amputation of part or all of a digit) 1. Fluoxetine 20 mg/day 2. Omega-3 10 caps/day marine triglycerides 3. Gamolenic acid 12 caps/day 4. Thymoxamine 40-80 mg QID (2 wk trial) 5. Iloprost IV Up to 3 ug/hour over 6 hrs for 3-7 days 6. Prostaglandin E1 60 ug in 250 cc over 3h for 3-7 days 1. Prednisone for brief periods of time early in the disease and primarily for edema 2. Methotrexate 3. D-Penicillamine 4. Cytoxan or Imuran 5. Gleevac 6. Thalidomide type compounds may have future promise 1. Bosentan 2. PDE4-Inhibitors (Sildenafil) 3. Prostaglandin vasodilators 1. ACEs or ARBs and strict BP control (benefits early without hypertension?) 2. High dose corticosteroids should be avoided for any manifestations in general as they may lead to a renal crisis and should not usually exceed 15 mg/day 1. Aggresssive use of PPIs and H2s (higher doses than usual?) 2. Metoclopramide ? 3. Dilatation 4. Surgery? 1. This is where high dose steroids may be used especially for severe myositis but with close monitoring of blood pressure 2. Methotrexate, Imuran, Cytoxan 1. Diuretics 2. ACEs 1. Monoclonal Antibodies or Anticytokine Compounds that inhibit profibrotic signaling pathways 2. Immune Modulators-Belimumab, and Abatacept 3. Stem Cell Transplants • This patient is 55 year old female with about a 10 year history of slight facial tightening but no sclerodactyly and no widespread skin tightening. She has a + SCL-70 ab. The raynauds has caused severe digital ischemia and loss of the ends of 3 fingers. About 3 years she began to develop severe SOB. Subsequently by open lung biopsy she was found to have sever interstitial pneumonitis and fibrosis. IV cytoxan times 6 months has helped stabilize her. Does she have Scleroderma? I believe so in spite of no skin involvment. • This patient is a 55 yr old female with a + ANA of 1:640 in a speckled pattern. She has very severe GERD, very resistant to treatment and pretty severe Raynauds also difficult to treat with frequent pitting ulcers on her finger tips and periungual infections. There has been no skin involvement and no CP or renal disease. Does she have Scleroderma? I believe she best fits into a “sine scleroderma” type picture. • This patient is a 60 year old female with about 8-10 years of moderate Raynauds with a + SCL-70 ab. She has prominent facial telangiectasias and moderate facial tightening and mild Sclerodactyly but no proximal sclerodermatous changes. She has borderline pulmonary HTN but no other internal manifestations. She does have distal finger pulp loss and significant acroosteolysis. Does she have Scleroderma? Yes and even though she clinically sounds like she has CREST this is probably better classified as diffuse SCL. 1. Scleroderma (limited and diffuse) always causes significant skin tightening. 2. ANA abs are always positive in the scleroderma syndromes. 3. Symptoms can involve lung, skin, GI, vascular, heart, and renal. 4. Raynauds is always bad in the scleroderma conditions. 5. Treatment of various symptoms is 0% 0% 0% 0% 0% always easy. 1 2 3 4 10 5 Countdown .
Load more

Recommended publications
  • Understanding and Managing Scleroderma
    Understanding and Managing Scleroderma A publication of Scleroderma Foundation 300 Rosewood Drive, Suite 105 Danvers, MA 01923 Maureen D. Mayes, M.D., M.P.H. Understanding and Understanding My notes and Managing Scleroderma Managing Scleroderma This booklet is intended to help people with scleroderma, their families and others interested ________________________ in learning more about the disease to better understand what scleroderma is, what effects ________________________ it may have, and what those with scleroderma can do to help themselves and their physicians ________________________ manage the disease. It answers some of the most frequently asked questions about ________________________ A publication of Maureen D. Mayes, M.D., M.P.H. Scleroderma Foundation 300 Rosewood Drive, Suite 105 scleroderma. Danvers, MA 01923 800-722-HOPE (4673) www.scleroderma.org www.facebook.com/sclerodermaUS www.twitter.com/scleroderma ________________________ Disclaimer The Scleroderma Foundation does not provide medical advice nor does it ________________________ endorse any drug or treatment mentioned herein. ________________________ The material contained in this booklet is presented for general information only. It is not intended to provide medical advice, to answer questions specific to the condition or problems of particular individuals, nor in ________________________ any way to substitute for the professional advice and care of qualified physicians. Mention of particular drugs and/or treatments is for ________________________ information purposes only and does not constitute an endorsement of said drugs and/or treatments. ________________________ Thanks! ________________________ The Scleroderma Foundation expresses its deep appreciation to the many ________________________ physicians whose efforts have led to this booklet. Special thanks are owed to Maureen D. Mayes, M.D., M.P.H., of the ________________________ University of Texas McGovern Medical School, Houston.
    [Show full text]
  • Dermatological Findings in Common Rheumatologic Diseases in Children
    Available online at www.medicinescience.org Medicine Science ORIGINAL RESEARCH International Medical Journal Medicine Science 2019; ( ): Dermatological findings in common rheumatologic diseases in children 1Melike Kibar Ozturk ORCID:0000-0002-5757-8247 1Ilkin Zindanci ORCID:0000-0003-4354-9899 2Betul Sozeri ORCID:0000-0003-0358-6409 1Umraniye Training and Research Hospital, Department of Dermatology, Istanbul, Turkey. 2Umraniye Training and Research Hospital, Department of Child Rheumatology, Istanbul, Turkey Received 01 November 2018; Accepted 19 November 2018 Available online 21.01.2019 with doi:10.5455/medscience.2018.07.8966 Copyright © 2019 by authors and Medicine Science Publishing Inc. Abstract The aim of this study is to outline the common dermatological findings in pediatric rheumatologic diseases. A total of 45 patients, nineteen with juvenile idiopathic arthritis (JIA), eight with Familial Mediterranean Fever (FMF), six with scleroderma (SSc), seven with systemic lupus erythematosus (SLE), and five with dermatomyositis (DM) were included. Control group for JIA consisted of randomly chosen 19 healthy subjects of the same age and gender. The age, sex, duration of disease, site and type of lesions on skin, nails and scalp and systemic drug use were recorded. χ2 test was used. The most common skin findings in patients with psoriatic JIA were flexural psoriatic lesions, the most common nail findings were periungual desquamation and distal onycholysis, while the most common scalp findings were erythema and scaling. The most common skin finding in patients with oligoarthritis was photosensitivity, while the most common nail finding was periungual erythema, and the most common scalp findings were erythema and scaling. We saw urticarial rash, dermatographism, nail pitting and telogen effluvium in one patient with systemic arthritis; and photosensitivity, livedo reticularis and periungual erythema in another patient with RF-negative polyarthritis.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Biology and Management of Unusual Plasma Cell Dyscrasias
    Todd M. Zimmerman Shaji K. Kumar Editors Biology and Management of Unusual Plasma Cell Dyscrasias 123 Biology and Management of Unusual Plasma Cell Dyscrasias Todd M. Zimmerman • Shaji K. Kumar Editors Biology and Management of Unusual Plasma Cell Dyscrasias 123 Editors Todd M. Zimmerman, MD Shaji K. Kumar, MD Section of Hematology/Oncology Division of Hematology, The University of Chicago Department of Medicine Chicago, IL, USA Mayo Clinic Rochester, MN, USA ISBN 978-1-4419-6847-0 ISBN 978-1-4419-6848-7 (eBook) DOI 10.1007/978-1-4419-6848-7 Library of Congress Control Number: 2016940068 © Springer Science+Business Media New York 2017 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made.
    [Show full text]
  • A Acanthosis Nigricans, 139 Acquired Ichthyosis, 53, 126, 127, 159 Acute
    Index A Anti-EJ, 213, 214, 216 Acanthosis nigricans, 139 Anti-Ferc, 217 Acquired ichthyosis, 53, 126, 127, 159 Antigliadin antibodies, 336 Acute interstitial pneumonia (AIP), 79, 81 Antihistamines, 324 Adenocarcinoma, 115, 116, 151, 173 Anti-histidyl-tRNA-synthetase antibody Adenosine triphosphate (ATP), 229 (Anti-Jo-1), 6, 14, 140, 166, 183, Adhesion molecules, 225–226 213–216 Adrenal gland carcinoma, 115 Anti-histone antibodies (AHA), 174, 217 Age, 30–32, 157–159 Anti-Jo-1 antibody syndrome, 34, 129 Alanine aminotransferase (ALT, ALAT), 16, Anti-Ki-67 antibody, 247 128, 205, 207, 255 Anti-KJ antibodies, 216–217 Alanyl-tRNA synthetase, 216 Anti-KS, 82 Aldolase, 14, 16, 128, 129, 205, 207, 255, 257 Anti-Ku antibodies, 163, 165, 217 Aledronate, 325 Anti-Mas, 217 Algorithm, 256, 259 Anti-Mi-2 Allergic contact dermatitis, 261 antibody syndrome, 11, 129, 215 Alopecia, 62, 199, 290 antibodies, 6, 15, 129, 142, 212 Aluminum hydroxide, 325, 326 Anti-Myo 22/25 antibodies, 217 Alzheimer’s disease-related proteins, 190 Anti-Myosin scintigraphy, 230 Aminoacyl-tRNA synthetases, 151, 166, 182, Antineoplastic agents, 172 212, 215 Antineoplastic medicines, 169 Aminoquinolone antimalarials, 309–310, 323 Antinuclear antibody (ANA), 1, 141, 152, 171, Amyloid, 188–190 172, 174, 213, 217 Amyopathic DM, 6, 9, 29–30, 32–33, 36, 104, Anti-OJ, 213–214, 216 116, 117, 147–153 Anti-p155, 214–215 Amyotrophic lateral sclerosis, 263 Antiphospholipid syndrome (APS), 127, Antisynthetase syndrome, 11, 33–34, 81 130, 219 Anaphylaxi, 316 Anti-PL-7 antibody, 82, 214 Anasarca,
    [Show full text]
  • Vasculitis in Systemic Sclerosis
    Hindawi Publishing Corporation International Journal of Rheumatology Volume 2010, Article ID 385938, 9 pages doi:10.1155/2010/385938 Review Article Vasculitis in Systemic Sclerosis Lily Kao and Cornelia Weyand Division of Immunology and Rheumatology, School of Medicine, Stanford University, Stanford, 1000 Welch Road, Suite #203, Palo Alto, CA 94304, USA Correspondence should be addressed to Lily Kao, [email protected] Received 14 May 2010; Accepted 17 July 2010 Academic Editor: Laura K. Hummers Copyright © 2010 L. Kao and C. Weyand. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic sclerosis (SSc) is a multiorgan connective tissue disease characterized by autoantibody production and fibroproliferative stenosis of the microvasculature. The vascoluopathy associated with SSc is considered to be noninflammatory, yet frank vasculitis can complicate SSc, posing diagnostic and therapeutic challenges. Here, we have reviewed the literature for reports of small-, medium-, and large-vessel vasculitis occurring in SSc. Amongst 88 reported cases of vasculitis in SSc, patients with ANCA-associated vasculitis appear to present a unique subclass in that they combined typical features of SSc with the renal manifestation of ANCA-associated glomerulonephritis. Other vasculitic syndromes, including large-vessel vasculitis, Behcet’s disease, cryoglobulinemia, and polyarteritis nodosa, are rarely encountered in SSc patients. ANCA-associated vasculitis needs to be considered as a differential diagnosis in SSc patients presenting with renal insufficiency, as renal manifestations may result from distinct disease processes and require appropriate diagnostic testing and treatment. 1. Introduction 2.
    [Show full text]
  • Beneath the Surface: Derm Clues to Underlying Disorders
    Christian R. Halvorson, MD; Richard Colgan, MD Department of Family and Beneath the surface: Derm clues Community Medicine, University of Maryland School of Medicine, Baltimore to underlying disorders [email protected] Dermatologic fi ndings are frequent indicators of The authors reported no potential confl ict of interest connective tissue disorders. Here’s what to look for. relevant to this article. any systemic conditions are accompanied by skin PRACTICE manifestations. Th is is especially true for connec- RECOMMENDATIONS Mtive tissue disorders, for which dermatologic fi nd- › When evaluating patients ings are often the key to diagnosis. with suspected cutaneous In this review, we describe the dermatologic fi ndings of lupus erythematosus, use some well-known connective tissue disorders. Th e text and multiple criteria—including photographs in the pages that follow will help you hone your histologic and immuno- diagnostic skills, leading to earlier treatment and, possibly, fl uorescent biopsy fi ndings better outcomes. and American College of Rheumatology criteria—to rule out systemic disease. C Lupus erythematosus: Cutaneous › Cancer screening with a and systemic disease often overlap careful history and physi- Lupus erythematosus (LE), a chronic, infl ammatory autoim- cal examination is recom- mended for all adult patients mune condition that primarily aff ects women in their 20s and whom you suspect of having 30s, may initially present as a systemic disease or in a purely dermatomyositis. C cutaneous form. However, most patients with systemic LE have some skin manifestations, and those with cutaneous › Suspect mixed connective LE often have—or subsequently develop—systemic involve- tissue disease in patients 1 with skin fi ndings charac- ment.
    [Show full text]
  • Clinical Aspects of Systemic Sclerosis (Scleroderma)
    854 Annals of the Rheumatic Diseases 1991; So: 854-861 Clinical aspects of systemic sclerosis (scleroderma) Richard M Silver Systemic sclerosis (scleroderma) is a disease of course of the illness, one hopes to identify unknown cause, the hallmark of which is patients at greater or lesser risk of developing induration of the skin. Although long regarded certain visceral complications, as well as provide as a bland fibrotic process, there is now ample a more homogeneous group of patients for evidence of an active inflammatory process studies of the pathogenesis, clinical manifesta- underlying thepathogenesisofsystemic sclerosis. tions, and treatment. In addition, microvascular disease and immuno- logical abnormalities are present in most cases. It remains to be determined just how the Clinical features immunological and microvascular changes RAYNAUD'S PHENOMENON relate to the overproduction of collagen and Raynaud's phenomenon refers to episodic digital other matrix elements by the fibroblast, but ischaemia provoked by cold or emotion. recent data suggest that products of the immune Although classically described as triphasic- response may directly affect fibroblasts and that is, pallor followed by cyanosis, and then endothelial cells in vitro. hyperaemia accompanied by numbness and This review will focus on recent advances in pain, such a three colour response does not the understanding of several clinical aspects of occur universally. Pallor seems to be the most systemic sclerosis. The reader is referred to reliable sign and hyperaemia the least reliable several recent chapters and textbooks for a more sign in subjects who lack the classic triphasic extensive review. 1-3 response. A recently described questionnaire and colour chart may facilitate the diagnosis of Raynaud's phenomenon.6 Classification Establishment of the presence or absence of Scleroderma may exist as a localised or a Raynaud's phenomenon is important when systemic disease process.
    [Show full text]
  • Review Article Vasculitis in Systemic Sclerosis
    Hindawi Publishing Corporation International Journal of Rheumatology Volume 2010, Article ID 385938, 9 pages doi:10.1155/2010/385938 Review Article Vasculitis in Systemic Sclerosis Lily Kao and Cornelia Weyand Division of Immunology and Rheumatology, School of Medicine, Stanford University, Stanford, 1000 Welch Road, Suite #203, Palo Alto, CA 94304, USA Correspondence should be addressed to Lily Kao, [email protected] Received 14 May 2010; Accepted 17 July 2010 Academic Editor: Laura K. Hummers Copyright © 2010 L. Kao and C. Weyand. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Systemic sclerosis (SSc) is a multiorgan connective tissue disease characterized by autoantibody production and fibroproliferative stenosis of the microvasculature. The vascoluopathy associated with SSc is considered to be noninflammatory, yet frank vasculitis can complicate SSc, posing diagnostic and therapeutic challenges. Here, we have reviewed the literature for reports of small-, medium-, and large-vessel vasculitis occurring in SSc. Amongst 88 reported cases of vasculitis in SSc, patients with ANCA-associated vasculitis appear to present a unique subclass in that they combined typical features of SSc with the renal manifestation of ANCA-associated glomerulonephritis. Other vasculitic syndromes, including large-vessel vasculitis, Behcet’s disease, cryoglobulinemia, and polyarteritis nodosa, are rarely encountered in SSc patients. ANCA-associated vasculitis needs to be considered as a differential diagnosis in SSc patients presenting with renal insufficiency, as renal manifestations may result from distinct disease processes and require appropriate diagnostic testing and treatment. 1. Introduction 2.
    [Show full text]
  • ESVM Guidelines – the Diagnosis and Management of Raynaud's Phenomenon
    413 Review ESVM guidelines – the diagnosis and management of Raynaud’s phenomenon Writing group Jill Belch1, Anita Carlizza2, Patrick H. Carpentier3, Joel Constans4, Faisel Khan1, and Jean-Claude Wautrecht5 1 University of Dundee School of Medicine, Dundee, United Kingdom 2 Azienda Ospedaliera S.Giovanni-Addolorata, Rome, Italy 3 Grenoble University Hospital, Grenoble, France 4 Hopital St Andre, Bordeaux, France 5 Cliniques universitaires de Bruxelles, Brussels, Belgium ESVM board authors Adriana Visona6, Christian Heiss7, Marianne Brodeman8, Zsolt Pécsvárady9, Karel Roztocil10, Mary-Paula Colgan11, Dragan Vasic12, Anders Gottsäter13, Beatrice Amann-Vesti14, Ali Chraim15, Pavel Poredoš16, Dan-Mircea Olinic17, Juraj Madaric18, and Sigrid Nikol19 6 Angiology Unit, Azienda ULSS 2, Marca Trevigiana, Treviso, Italy 7 Department of Cardiology, Pulmonology and Vascular Medicine, Düsseldorf, Germany 8 Division of Angiology, Medical University, Graz, Austria 9 Head of 2nd Dept. of Internal Medicine, Vascular Center, Flor Ferenc Teaching Hospital, Kistarcsa, Hungary 10 Institute of Clinical and Experimental Medicine, Prague, Czech Republic 11 St. James’s Hospital and Trinity College, Dublin, Ireland 12 Clinical Centre of Serbia, Belgrade, Serbia 13 Department of Vascular Diseases, Skåne University Hospital, Sweden 14 Clinic for Angiology, University Hospital Zurich, Switzerland 15 Department of Vascular Surgery, Cedrus Vein and Vascular Clinic, Lviv Hospital, Lviv, Ukraine 16 University Medical Centre Ljubljana, Slovenia 17 Medical Clinic no. 1,
    [Show full text]
  • Characteristic Electron-Microscopic Features of Cryofibrinogen
    Ibuki et al. BMC Nephrology (2020) 21:27 https://doi.org/10.1186/s12882-020-1696-0 CASE REPORT Open Access Characteristic electron-microscopic features of cryofibrinogen-associated glomerulonephritis: a case report Emi Ibuki1*† , Aiko Shiraishi2†, Tadashi Sofue2, Yoshio Kushida1, Kyuichi Kadota1, Kazuho Honda3, Dedong Kang3, Kensuke Joh4, Tetsuo Minamino2 and Reiji Haba1 Abstract Background: Cryofibrinogenemia is a rare disorder that mainly affects the skin and occasionally the kidney. However, there are few published reports of cryofibrinogenemia-associated renal pathology. We therefore report a patient with cryofibrinogen-associated glomerulonephritis. Samples from this patient were examined by electron microscopy, laser microdissection, and liquid chromatography-tandem mass spectrometry (LC-MS/MS). Case presentation: A 78-year-old Japanese man presented with declining renal function, proteinuria, and gross hematuria. Kidney biopsy showed a membranoproliferative pattern with crescent formation and dominant C3c deposition in which subendothelial deposits with uniquely organized electron-microscopic features were observed. Additional ultrastructural analysis of cryoprecipitates extracted from plasma revealed similar structures of the glomerular subendothelial deposits. LC-MS/MS identified an increase in fibrinogen α, β, and γ chains, fibronectin, filamin-A, and C3. The glomerular lesions were diagnosed as cryofibrinogen-associated glomerulonephritis on the basis of these findings. Conclusions: Although there are few reports of cryofibrinogen-associated
    [Show full text]
  • Vascular Disease in Systemic Sclerosis
    International Journal of Rheumatology Vascular Disease in Systemic Sclerosis Guest Editors: Lorinda Chung, Oliver Distler, Laura Hummers, Eswar Krishnan, and Virginia Steen Vascular Disease in Systemic Sclerosis International Journal of Rheumatology Vascular Disease in Systemic Sclerosis Guest Editors: Lorinda Chung, Oliver Distler, Laura Hummers, Eswar Krishnan, and Virginia Steen Copyright © 2010 Hindawi Publishing Corporation. All rights reserved. This is a special issue published in volume 2010 of “International Journal of Rheumatology.” All articles are open access articles dis- tributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. International Journal of Rheumatology Editorial Board Salvatore M. F. Albani, USA Shinichi Kawai, Japan Lisa G. Rider, USA Ernest Brahn, USA Charles J. Malemud, USA Vicente Rodriguez-Valverde, Spain Ruben Burgos-Vargas, Mexico Johanne Martel-Pelletier, Canada Bruce M. Rothschild, USA Dirk Elewaut, Belgium Terr y L. Moore, USA J. R. Seibold, USA Luis R. Espinoza, USA Ewa Paleolog, UK Leonard H. Sigal, USA Barri J. Fessler, USA Thomas Pap, Germany Malcolm Smith, Australia Piet Geusens, Belgium Karel Pavelka, Czech Republic G. C. Tsokos, USA Hiroshi Hashimoto, Japan Jean-Pierre Pelletier, Canada Ronald van Vollenhoven, Sweden Sergio Jimenez, USA Proton Rahman, Canada Muhammad B. Yunus, USA Kenneth C. Kalunian, USA Morris Reichlin, USA Contents Vascular Disease in Systemic Sclerosis, Lorinda Chung, Oliver Distler, Laura Hummers, Eswar Krishnan, and Virginia Steen Volume 2010, Article ID 714172, 2 pages The Vascular Microenvironment and Systemic Sclerosis, Tracy Frech, Nathan Hatton, Boaz Markewitz, Mary Beth Scholand, Richard Cawthon, Amit Patel, and Allen Sawitzke Volume 2010, Article ID 362868, 6 pages Digital Ischemia in Scleroderma Spectrum of Diseases, Elena Schiopu, Ann J.
    [Show full text]